Dose-creep of Infliximab during psoriasis treatment: an observational study

Acta Derm Venereol. 2012 Jul;92(4):355-7. doi: 10.2340/00015555-1230.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Denmark
  • Dose-Response Relationship, Drug
  • Drug Dosage Calculations
  • Female
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Odds Ratio
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / metabolism
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • Infliximab